For Healthcare Professionals

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine.

clipboard-pencil

About the study

The purpose of this second extension study is to collect long-term safety and tolerability data and additional efficacy data in patients who are treated on demand upon flare with canakinumab.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Patients who have either:

  1. Completed the first extension study CACZ885H2357E1 or
  2. Experienced a ninth new flare within the core study CACZ885H2357 and the first extension study CACZ885H2357E1

EXCLUSION CRITERIA

  1. Continuation in this extension study is considered inappropriate by the treating physician
  2. Pregnant or nursing (lactating) women
  3. Female patients being physiologically capable of becoming pregnant UNLESS they are using an acceptable method of contraception with a failure rate (Pearl Index (PI)) < 1 Other protocol defined inclusion/exclusion criteria may apply.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall +41-61-324-1111

Study’s details


Contition

Acute Gout

Age

18+

Phase

Phase 3

Participants needed

175

Est. Completion Date

Invalid Date

Treatment type

Interventional


Sponsor

Novartis

ClinicalTrials.gov identifier

NCT01194921

Study number

CACZ885H2357E2

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.